Company Overview

OticPharma, established in 2008, is a private clinical-stage pharmaceutical company focusing on the acquisition and development of ear, nose, and throat (ENT) products that restore health and address unmet needs in children and adults.  The company’s proprietary foam technology (OP-01) is currently being developed for acute otitis externa (“swimmers ear”) and is also being explored for the treatment of nasal and sinus conditions.  The company’s proprietary surfactant pharmaceutical product (OP-02) is currently being developed as a potential first-in-class, antibiotic-free treatment option for acute, recurrent, and chronic otitis media.

About OP-01 Foam

OP-01 is a novel, investigational pharmaceutical delivery platform that has the potential to overcome the major challenges of treating otolaryngology disorders.  These challenges include insufficient coverage, drug residence time, the need for repeated and frequent administration and in cases of the external ear canal, the need to tilt the head sideways and remain lying down.

About OP-02 Surfactant

OP-02 is a novel, investigational pharmaceutical product that has the potential to treat conditions of the middle and inner ear by restoring function of the Eustachian tube (ET) and thereby preventing Otitis Media (inflammation of the middle ear) and related morbidities.

About Acute Otitis Externa

Acute otitis externa (AOE) or “swimmer’s ear” is a generalized inflammation of the epithelium of the external ear canal which may also involve the pinna and/or the tympanic membrane (eardrum).  It is variably characterized by erythema, edema, increased sebum or exudates, and desquamation of the epithelium.  The vast majority of the cases of AOE are due to bacterial infections.  The common treatment of AOE consists of antibiotics, with or without steroids, analgesics and water avoidance.  Otic preparations are generally supplied in the form of liquid ear drops which are administered multiple times per day.

About Otitis Media

Otitis media is a generalized inflammation of the middle ear space behind the tympanic membrane (eardrum), which can occur with or without infection.  When infection occurs, the initial condition is referred to as acute otitis media (AOM) and when the fluid persists in the middle ear space it becomes otitis media with effusion (OME).  Recurrent and persistent cases of otitis media can become quite burdensome for patients, and can result in language and learning delays in young children.  In older children and adults, chronic forms of otitis media can result in damage to the tympanic membrane and other structures of the middle ear and can lead to permanent hearing loss and other complications.  Symptoms may include ear pain, pressure, fever, drainage, vertigo, tinnitus, and hearing loss.